• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Y. Yoshitake, T. Nakatsura, +13 authors Y. Nishimura
  • Biology, Medicine
  • Clinical Cancer Research
  • 2004 (First Publication: 1 October 2004)
  • Purpose: To establish effective antitumor immunotherapy for esophageal cancer, we tried to identify an useful target antigen of esophageal cancer. Experimental Design: We did cDNA microarray analysisExpand
  • Katsunori Imai, Shinya Hirata, +11 authors Yasuharu Nishimura
  • Medicine
  • Clinical Cancer Research
  • 2008 (First Publication: 15 October 2008)
  • Purpose: To establish cancer immunotherapy, it is important to identify the tumor-associated antigens (TAA) that are strongly expressed in the tumor cells but not in the normal cells. In this study,Expand
  • Yoshiaki Ikuta, Toshiharu Okugawa, +7 authors Hiroshi Shiku
  • Biology, Medicine
  • International journal of cancer
  • 2000 (First Publication: 15 August 2000)
  • We have identified an H-2K(d)-binding peptide, HER2p780 (PYVSRLLGI), derived from murine HER2/neu (HER2), that can induce HER2-specific murine cytotoxic T lymphocytes (CTL). Weekly vaccination ofExpand
  • E. Fujimoto, M. Ochi, Y. Kato, Y. Mochizuki, Y. Sumen, Y. Ikuta
  • Medicine
  • Archives of Orthopaedic and Trauma Surgery
  • 1999 (First Publication: 18 May 1999)
  • Abstract The effects of exogenous basic fibroblast growth factor (bFGF) on the repair of full-thickness cartilage defects were examined. Four-millimeter diameter, cylindrical defects were made inExpand
  • T. Okugawa, Y. Ikuta, +8 authors H. Shiku
  • Biology, Medicine
  • European journal of immunology
  • 2000 (First Publication: 1 November 2000)
  • A mouse HER2-derived peptide, HER2p63 (A) (TYLPANASL), can induce K(d)-restricted mouse cytotoxic T lymphocytes (CTL) and also function as a tumor rejection antigen in an in vivo assay. Since theExpand
  • M. Harao, S. Hirata, +16 authors Y. Nishimura
  • Medicine
  • International journal of cancer
  • 2008 (First Publication: 1 December 2008)
  • Toward the development of a novel cancer immunotherapy, we have previously identified several tumor-associated antigens (TAAs) and the epitopes recognized by human histocompatibility leukocyteExpand